PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34858188-0	2021	Farrerol Ameliorated Cisplatin-Induced Chronic Kidney Disease Through Mitophagy Induction via Nrf2/PINK1 Pathway.	farrerol	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	94-98	
34858188-1	2021	Previously, Our study has showed that farrerol can activate Nrf2 and ameliorate cisplatin-induced acute kidney injury (AKI).	farrerol	38-46	nuclear factor, erythroid derived 2, like 2	Mus musculus	60-64	
34858188-3	2021	In this study, we evaluated the correlation between mitophagy and the protective effect of the Nrf2 activator farrerol on cisplatin-induced CKD by using C57BL/6 wild-type and Nrf2 knockout mice.	farrerol	110-118	nuclear factor, erythroid derived 2, like 2	Mus musculus	95-99	
34858188-5	2021	Similar to previous results, farrerol activated Nrf2 on the 38th day of cisplatin administration, subsequently stimulating the Nrf2-targeted antioxidant enzymes HO-1 and NQO1.	farrerol	29-37	nuclear factor, erythroid derived 2, like 2	Mus musculus	48-52	
34858188-5	2021	Similar to previous results, farrerol activated Nrf2 on the 38th day of cisplatin administration, subsequently stimulating the Nrf2-targeted antioxidant enzymes HO-1 and NQO1.	farrerol	29-37	nuclear factor, erythroid derived 2, like 2	Mus musculus	127-131	
34858188-9	2021	These data indicated that farrerol effectively inhibited cisplatin-induced inflammation and renal fibrosis by activating Nrf2 and PINK1/Parkin-mediated mitophagy, which provides a potential novel therapeutic target for CKD.	farrerol	26-34	nuclear factor, erythroid derived 2, like 2	Mus musculus	121-125